IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Top Cited Papers
- 19 June 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 18 (9), 545-558
- https://doi.org/10.1038/s41577-018-0029-z
Abstract
IFNγ is a cytokine with important roles in tissue homeostasis, immune and inflammatory responses and tumour immunosurveillance. Signalling by the IFNγ receptor activates the Janus kinase (JAK)–signal transducer and activator of transcription 1 (STAT1) pathway to induce the expression of classical interferon-stimulated genes that have key immune effector functions. This Review focuses on recent advances in our understanding of the transcriptional, chromatin-based and metabolic mechanisms that underlie IFNγ-mediated polarization of macrophages to an ‘M1-like’ state, which is characterized by increased pro-inflammatory activity and macrophage resistance to tolerogenic and anti-inflammatory factors. In addition, I describe the newly discovered effects of IFNγ on other leukocytes, vascular cells, adipose tissue cells, neurons and tumour cells that have important implications for autoimmunity, metabolic diseases, atherosclerosis, neurological diseases and immune checkpoint blockade cancer therapy.Keywords
This publication has 124 references indexed in Scilit:
- CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon ResponseImmunity, 2013
- Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseasesProceedings of the National Academy of Sciences of the United States of America, 2012
- NF-κB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin toleranceNature Immunology, 2012
- Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneityArthritis & Rheumatism, 2011
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences of the United States of America, 2011
- 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling responseNature, 2011
- Interferon-γ links ultraviolet radiation to melanomagenesis in miceNature, 2011
- IFN-γ abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodelingProceedings of the National Academy of Sciences of the United States of America, 2010
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune DiseasesImmunity, 2009
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences of the United States of America, 2008